These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
207 related items for PubMed ID: 14682224
21. Urinary N-acetyl-beta-D-glucosaminidase (NAG) in lupus nephritis and rheumatoid arthritis. Erdener D, Aksu K, Biçer I, Doğanavşargil E, Kutay FZ. J Clin Lab Anal; 2005; 19(4):172-6. PubMed ID: 16025478 [Abstract] [Full Text] [Related]
22. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431 [Abstract] [Full Text] [Related]
23. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. Rau R, Schleusser B, Herborn G, Karger T. J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088 [Abstract] [Full Text] [Related]
24. Potential role of poly(ADP-ribose) polymerase (PARP) activation in methotrexate-induced nephrotoxicity and tubular apoptosis. Dalaklioglu S, Sahin P, Ordueri EG, Celik-Ozenci C, Tasatargil A. Int J Toxicol; 2012 Aug; 31(5):430-40. PubMed ID: 22914891 [Abstract] [Full Text] [Related]
25. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269 [Abstract] [Full Text] [Related]
26. [Urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in women with preeclampsia]. Semczuk-Sikora A, Sikora P, Semczuk M. Ginekol Pol; 2000 Mar; 71(3):141-5. PubMed ID: 10842915 [Abstract] [Full Text] [Related]
27. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor. Hjeltnes G, Hollan I, Førre O, Wiik A, Lyberg T, Mikkelsen K, Agewall S. Clin Exp Rheumatol; 2013 Mar; 31(3):415-21. PubMed ID: 23465067 [Abstract] [Full Text] [Related]
28. Renal disease in rheumatoid arthritis. Dieppe PA, Doyle DV, Burry HC, Tucker SM. Br Med J; 1976 Mar 13; 1(6010):611-2. PubMed ID: 1252848 [Abstract] [Full Text] [Related]
29. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. Kremer JM, Hamilton RA. J Rheumatol; 1995 Nov 13; 22(11):2072-7. PubMed ID: 8596147 [Abstract] [Full Text] [Related]
30. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Arthritis Rheum; 2011 Dec 13; 63(12):3723-32. PubMed ID: 21834061 [Abstract] [Full Text] [Related]
31. Monitoring methotrexate therapy in patients with rheumatoid arthritis. Wiela-Hojenska A, Orzechowska-Juzwenko K, Swierkot J, Wiland P, Hurkacz M, Szechinski J. Int J Clin Pharmacol Ther; 2004 Aug 13; 42(8):434-41. PubMed ID: 15366323 [Abstract] [Full Text] [Related]
32. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis. Schiff MH, Sadowski P. Rheumatol Int; 2017 Feb 13; 37(2):213-218. PubMed ID: 28012023 [Abstract] [Full Text] [Related]
33. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Hempel L, Misselwitz J, Fleck C, Kentouche K, Leder C, Appenroth D, Rost M, Zintl F. Med Pediatr Oncol; 2003 Jun 13; 40(6):348-54. PubMed ID: 12692801 [Abstract] [Full Text] [Related]
34. Renal tubular function of workers exposed to low levels of cadmium. Chia KS, Ong CN, Ong HY, Endo G. Br J Ind Med; 1989 Mar 13; 46(3):165-70. PubMed ID: 2649143 [Abstract] [Full Text] [Related]
35. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. Arthritis Rheum; 2012 Apr 13; 64(4):970-81. PubMed ID: 22006202 [Abstract] [Full Text] [Related]
36. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. Luis M, Pacheco-Tena C, Cazarín-Barrientos J, Lino-Pérez L, Goycochea MV, Vazquez-Mellado J, Burgos-Vargas R. Arthritis Rheum; 1999 Oct 13; 42(10):2160-5. PubMed ID: 10524688 [Abstract] [Full Text] [Related]
37. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital. de Thurah A, Nørgaard M, Johansen M, Stengaard-Pedersen K. Scand J Rheumatol; 2010 Oct 13; 39(1):19-25. PubMed ID: 20132066 [Abstract] [Full Text] [Related]
39. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. J Rheumatol; 1995 May 13; 22(5):844-9. PubMed ID: 8587070 [Abstract] [Full Text] [Related]